Comparison of FLT3 inhibitors with the standard treatment for FLT3-ITD mutated acute myeloid leukemia
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, which is characterized by impaired differentiation and uncontrollable proliferation of myeloid progenitor cells in the bone marrow. One-third of patients with AML have a mutation in the FMS-like tyrosine kinase 3 (FLT3) gene. The...
Main Author: | Argetsinger, Stephanie |
---|---|
Other Authors: | MacNeil, Maryann |
Language: | en_US |
Published: |
2019
|
Subjects: | |
Online Access: | https://hdl.handle.net/2144/32984 |
Similar Items
-
Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Chen, Y., et al.
Published: (2022) -
NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
by: Shano Naseem, et al.
Published: (2021-01-01) -
The Role of the Juxtamembrane Domain of FLT3-ITDs in Acute Myeloid Leukemia
by: Vempati, Sridhar
Published: (2007) -
Mechanism of sorafenib resistance in FLT3-ITD⁺ acute myeloid leukemia
by: Man, Cheuk-him, et al.
Published: (2014) -
FMS-LIKE TYROSINE KINASE (FLT3) GENE ITD MUTATION IN ACUTE MYELOID LEUKEMIA
by: Rajko Kusec, et al.
Published: (2004-12-01)